Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 11.0% in December

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 356,500 shares, a drop of 11.0% from the December 15th total of 400,500 shares. Approximately 2.2% of the company's stock are sold short. Based on an average daily volume of 165,700 shares, the short-interest ratio is currently 2.2 days.

Institutional Trading of Immix Biopharma

Several hedge funds have recently modified their holdings of IMMX. Geode Capital Management LLC raised its position in shares of Immix Biopharma by 5.6% during the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company's stock valued at $224,000 after buying an additional 7,954 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in Immix Biopharma during the fourth quarter valued at approximately $63,000. Finally, Invst LLC bought a new stake in shares of Immix Biopharma in the 2nd quarter valued at approximately $57,000. 11.26% of the stock is owned by hedge funds and other institutional investors.

Immix Biopharma Stock Down 1.0 %

NASDAQ:IMMX traded down $0.02 on Monday, reaching $2.04. 121,030 shares of the company's stock traded hands, compared to its average volume of 140,296. The stock has a 50-day simple moving average of $2.07 and a 200-day simple moving average of $1.94. Immix Biopharma has a 12 month low of $1.26 and a 12 month high of $5.73. The firm has a market cap of $56.12 million, a PE ratio of -2.40 and a beta of 0.27.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). On average, equities analysts anticipate that Immix Biopharma will post -0.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Immix Biopharma in a report on Monday, January 6th.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.